In a city where a common virus circulates without seasonal pause, Singapore's health authorities have approved a single-dose monoclonal antibody to shield its youngest and most vulnerable residents from respiratory syncytial virus. The approval of clesrovimab — marketed as ENFLONSIA by MSD — marks the first such clearance in the Asia-Pacific region, reflecting a broader reckoning with RSV not as an inevitable rite of infancy but as a preventable source of hospitalization and lasting harm. For families welcoming newborns into a tropical climate that offers no quiet season from the virus, this r
Singapore Approves MSD's ENFLONSIA to Prevent RSV Disease in Infants
RSV infections in infants can cause severe respiratory conditions including bronchiolitis and pneumonia, leading to hospitalization and long-term respiratory complications like asthma.
One shot, five to six months of protection against a virus that hospitalizes infants
Mark
Why does Singapore need another RSV preventive when palivizumab already exists?
Mimi
Palivizumab requires multiple injections throughout the season. ENFLONSIA is one shot, 105 milligrams, done. For a busy healthcare system and families managing newborns, that simplicity matters. It also lasts the full five to six months of the season.
Mark
Is RSV really that dangerous for most infants, or is this approval driven by pharmaceutical marketing?
Mimi
For most healthy full-term infants, RSV is a cold. But for premature babies, those with heart or lung conditions, or immunocompromised infants, it can mean hospitalization, breathing tubes, pneumonia. And even in healthy infants who recover, early RSV infection increases the risk of asthma later. That's not marketing—that's epidemiology.
Mark
Why is Singapore the first in Asia-Pacific to get this approval?
Mimi
Regulatory speed varies. Singapore's HSA moves efficiently, and MSD likely prioritized the region based on disease burden and healthcare infrastructure. But it also signals that other Asia-Pacific countries will probably follow.
Mark
What happens to infants whose families can't afford ENFLONSIA?
Mimi
That's the real question. The approval is one thing; access and affordability are another. Whether Singapore's public healthcare system covers it, and at what cost to families, will determine how much this approval actually changes outcomes on the ground.
Mark
Does one dose really protect for five to six months?
Mimi
That's what the trials showed. The monoclonal antibody circulates in the infant's bloodstream and gradually clears over that period. It's not immunity—the infant isn't building their own defense—but passive protection while they're most vulnerable.
O Pulso
- RSV infects nearly every child in Singapore before age two, but for premature infants and newborns with fragile immune systems, it can escalate into bronchiolitis, pneumonia, and hospitalization — with consequences that may echo into childhood as asthma.
- Unlike temperate countries where RSV follows winter patterns, Singapore's tropical climate keeps the virus circulating year-round, meaning no infant born at any point in the calendar is naturally safe from exposure.
- ENFLONSIA cuts through the complexity of existing prevention regimens by requiring just one fixed 105mg dose regardless of an infant's weight, simplifying protection at a moment when clinical simplicity can be lifesaving.
- Backed by two major clinical trials — one spanning preterm and full-term infants, another directly comparing it to the existing standard palivizumab — the drug arrives with a credible evidence base supporting its five-to-six-month protective window.
- Singapore's approval positions it as the first Asia-Pacific market to offer this option, giving pediatricians a new tool to tailor RSV prevention to individual risk profiles alongside existing therapies.
In a city where a common virus circulates without seasonal pause, Singapore's health authorities have approved a single-dose monoclonal antibody to shield its youngest and most vulnerable residents from respiratory syncytial virus. The approval of clesrovimab — marketed as ENFLONSIA by MSD — marks the first such clearance in the Asia-Pacific region, reflecting a broader reckoning with RSV not as an inevitable rite of infancy but as a preventable source of hospitalization and lasting harm. For families welcoming newborns into a tropical climate that offers no quiet season from the virus, this represents a meaningful expansion of what medicine can now offer at the threshold of life.
Singapore's Health Sciences Authority has approved clesrovimab, sold as ENFLONSIA by MSD, to prevent RSV lower respiratory tract disease in newborns and infants during their first RSV season. A single 105-milligram injection — the same dose for every infant regardless of weight — provides protection lasting five to six months, making it simpler to administer than alternatives requiring multiple doses.
RSV is a year-round presence in tropical Singapore, peaking between May and September, and nearly all children encounter it by age two. For most, it resembles a cold. But for premature infants or those too young to mount a strong immune response, the virus can cause bronchiolitis or pneumonia severe enough to require hospitalization. The risks don't end with recovery: early RSV infection raises the likelihood of recurrent wheezing and childhood asthma.
The drug works by targeting the RSV F protein, blocking the virus from infecting cells. Its approval rests on two clinical trials — the CLEVER trial, which enrolled preterm and full-term infants from birth to one year, and the SMART trial, which compared ENFLONSIA directly against palivizumab, the existing preventive standard.
Singapore is the first market in the Asia-Pacific region to approve the treatment, a milestone that reflects a shift in how RSV is understood — less as an unavoidable feature of infancy and more as a preventable cause of serious harm. Because the virus circulates throughout the year rather than in a defined winter season, infants born at any time may need protection, a reality that makes a simple, single-dose option particularly well suited to Singapore's epidemiological landscape.
Healthcare providers can now offer ENFLONSIA alongside existing options, giving clinicians greater flexibility to match prevention strategies to each infant's risk profile. For families, it represents a concrete possibility of keeping a newborn out of the hospital — and out of the longer shadow RSV can cast on a child's respiratory health.
Singapore's Health Sciences Authority has approved a new weapon against respiratory syncytial virus in infants: a monoclonal antibody called clesrovimab, marketed as ENFLONSIA by MSD. The drug is designed to prevent RSV lower respiratory tract disease in newborns and infants entering their first RSV season, offering protection that lasts five to six months with a single injection.
RSV is a virus that circulates year-round in tropical Singapore, with infection rates peaking between May and September. By age two, most children in the city-state have encountered it. For most, it causes cold-like symptoms. But for vulnerable infants—those born prematurely, those with certain underlying conditions, or simply those too young to mount a strong immune response—RSV can turn serious. The virus can trigger bronchiolitis, an inflammation of the small airways in the lungs, or pneumonia. It sends infants to hospitals. And the damage doesn't always end when the acute infection clears. Children who contract RSV early in life face a higher risk of recurrent wheezing and may develop asthma later in childhood.
The new drug works by targeting a specific protein on the RSV virus called the F protein, blocking the virus's ability to infect cells. Unlike some other preventive treatments, ENFLONSIA requires only one dose—105 milligrams, the same amount for every infant regardless of weight—making it simpler to administer than alternatives that require multiple injections over a season. The approval is based on two major clinical trials: the CLEVER trial, which tested the drug in both preterm and full-term infants from birth to one year old, and the SMART trial, which directly compared ENFLONSIA to palivizumab, an existing RSV preventive therapy.
Singapore becomes the first market in the Asia-Pacific region to approve this treatment. The timing reflects a broader shift in how pediatricians and public health officials think about RSV. For decades, the virus was largely accepted as an inevitable part of infancy. But as hospitalizations mounted and the long-term respiratory consequences became clearer, prevention moved higher on the priority list. Dr. Jenny Tang, a senior pediatrician at SBCC Baby & Child Clinic, noted that RSV remains a significant cause of infant hospitalization in Singapore and globally, and that early infection carries consequences that extend well beyond the initial illness.
The approval also reflects the particular epidemiology of Singapore, where RSV doesn't follow the winter seasonality of temperate countries but instead circulates throughout the year. This means infants born at any time of year may need protection. Dr. Agnihotri Biswas, head of neonatology at the National University Hospital's children's institute, emphasized that young infants and those born prematurely are at highest risk for severe disease, and that awareness about RSV prevention remains crucial for reducing hospitalizations.
Healthcare providers in Singapore can now offer ENFLONSIA to eligible newborns and infants. The drug represents an additional option alongside existing preventive treatments, giving clinicians more tools to tailor protection based on individual risk factors. For families with infants entering their first RSV season, it offers the possibility of preventing a serious respiratory infection—and the hospitalizations, complications, and long-term effects that can follow.
Citações Notáveis
RSV remains a significant cause of hospitalisation for infants in Singapore and globally. Beyond acute illness, RSV infection in early life has also been associated with a higher risk of subsequent respiratory morbidity, including recurrent wheezing and the development of asthma in childhood.— Dr Jenny Tang, Senior Consultant paediatrician, SBCC Baby & Child Clinic
Unlike many temperate countries with seasonal incidence in winter, RSV circulates throughout the year in a tropical country like Singapore. Young infants, prematurely born infants and children with certain pre-existing conditions are more likely to demonstrate severe symptoms when infected by RSV.— Adjunct Associate Professor Agnihotri Biswas, Head of Neonatology, National University Hospital
Quer a matéria completa?
Leia o original em BioSpectrum Asia ↗
Health & Medicine